Dalmia Cement (Bharat) Limited begins commercial production at Chunar plant
Dalmia Bharat · Cement & Cement Products
Key highlights
- Commercial production commenced on June 20, 2026, at the Chunar plant in Uttar Pradesh
- The plant has a cement grinding capacity of 2.5 MTPA
- This plant is part of Dalmia Cement (Bharat) Limited, a wholly owned material subsidiary of Dalmia Bharat Limited
Why it's rated notable: Commercial production began on June 20, 2026 at the recently acquired Chunar plant with 2.5 MTPA grinding capacity, and the filing states no amount, so the level stays at medium.
Original filing
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Commencement Of Commercial Production
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Dalmia Bharat
- Order winNotableDalmia Bharat's subsidiary DCBL identified as successful resolution applicant for BJCL
- Acquisition / mergerMajor development· Adverse for the businessDalmia Bharat reports Q1 FY27 unaudited results and appoints new CFO
- Acquisition / mergerMajor development· Adverse for the businessDalmia Bharat reports Q1 FY27 results; completes Central Region cement acquisition
- Acquisition / mergerNotableDalmia Bharat acquires cement plants adding 5.2 MnTPA capacity
- Board / shareholder meeting outcomeNotableDalmia Bharat Limited announces 13th AGM date and auditor re-appointment
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Cement & Cement Products
on management's own guidance
- J K CementsGood growth2
- Strong growth1
- ACCGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.